Navigation Links
After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Date:7/11/2013

EXTON, Pa., July 11, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, for late-phase products for chronic kidney disease (CKD) patients—including AbbVie's altrasentan, Concert Pharmaceuticals' CTP-499, Mitsubishi Tanabe's MP-146/AST-120, Fibrogen's FG3019, Pfizer's PF00487791 and PF04634817 and Eli Lilly's LY2382770—the percentage of likely candidates is typically, but not always highest, in Stage 3b and Stage 4. TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) also finds that, among physicians who treat CKD, familiarity with new products in development is low, but interest is generally high after reviewing brief product profiles.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The report also finds that among 250 surveyed nephrologists, endocrinologists and primary care physicians (PCPs), PCPs are significantly more likely than other physician groups to make the initial diagnosis of CKD, and PCPs account for the majority (51 percent) of the CKD non-dialysis patient referrals that nephrologists receive. Physicians report that CKD patients are most often diagnosed in Stage 3; nephrologists report CKD patients are diagnosed significantly later in the disease process compared with what PCPs and endocrinologists report.

 "Eighty-six percent of physicians believe that the ideal timing for a new CKD agent designed to slow disease progression would be either during treatment of patients with early symptoms or for asymptomatic patients," said BioTrends Research Group Director Rob Dubman. "Given this, these patients are likely to be with the PCP or endocrinologist at that point during the disease progression making these physician types important. Manufacturers in this market should therefore consider, at least to some extent, the impact of the PCP and endocrinologist in regard to patient referral and treatment."

Patient compliance is also a key issue in this patient population. The report finds that patients tend to be most compliant with antihypertensive agents and erythropoiesis stimulating agents (ESAs) and least compliant with phosphate binders and lifestyle changes.

TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) is a report series designed to track physician perception of the CKD non-dialysis patient population, including referral patterns, patient load, percentage of patients on current treatments, screening protocols, diagnosis patterns, frequency of comorbidities, unmet needs and reaction (familiarity, interest and percentage of patients as likely candidates) to new products in development. A total of 250 physicians are included in the third wave sample frame, including 100 nephrologists, 50 endocrinologists and 100 primary care physicians. The third wave of this report published in June 2013. 

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
3. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
4. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
5. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
6. Makers Of Over-the-Counter Inhaler Leading Fight To Have Product Back On Market After Removal Due To Environmental Treaty
7. Masimo to Report Second Quarter 2012 Financial Results after Market Close on August 1
8. Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
11. Protection Against Whooping Cough Waned During the Five Years After Fifth Dose of DTaP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Stock-Callers.com today evaluates the following ... ), Novo Nordisk A/S (NYSE: NVO ), Sucampo ... Holdings Inc. (NASDAQ: PTX ). These stocks belong ... th , 2017, finishing near its session lows. As per ... 0.7%, while shares of health care companies in the S&P ...
(Date:1/20/2017)... LONDON , January 20, 2017 Avillion ... the appointment of Mark Weinberg , MD MBA as Chief ... , USA . ... Dr Weinberg has spent more than 17 ... "top 20" pharma companies to micro-cap biotech. Over the course of ...
(Date:1/19/2017)... 19, 2017 The U.S. Food and Drug Administration ... Constipation (CIC) in adult patients. "No one ... said Julie Beitz , M.D., director of the Office ... Evaluation and Research. "With the availability of new therapies, patients ... their condition." ...
Breaking Medicine Technology:
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... ... ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to support ... author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, his ... of age, he joined the Navy and got married right out of boot camp. ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that ... of published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose ... since high school and have many different titles,” Gaapf mentions about his different works. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear for ... games that circumvent health needs of over 30 million. Many interviews with Dr. Carol ... needs government public servants were suppose to prioritize. Interviews provided below. , ...
Breaking Medicine News(10 mins):